<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37781035</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>14</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>International journal of biological sciences</Title><ISOAbbreviation>Int J Biol Sci</ISOAbbreviation></Journal><ArticleTitle>Activation of STING by SAMHD1 Deficiency Promotes PANoptosis and Enhances Efficacy of PD-L1 Blockade in Diffuse Large B-cell Lymphoma.</ArticleTitle><Pagination><StartPage>4627</StartPage><EndPage>4643</EndPage><MedlinePgn>4627-4643</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijbs.85236</ELocationID><Abstract><AbstractText>Genomic instability is a significant driver of cancer. As the sensor of cytosolic DNA, the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway plays a critical role in regulating anti-tumor immunity and cell death. However, the role and regulatory mechanisms of STING in diffuse large B-cell lymphoma (DLBCL) are still undefined. In this study, we reported that sterile alpha motif and HD domain-containing protein 1 (SAMHD1) deficiency induced STING expression and inhibited tumor growth in DLBCL. High level of SAMHD1 was associated with poor prognosis in DLBCL patients. Down-regulation of SAMHD1 inhibited DLBCL cell proliferation both <i>in vitro</i> and <i>in vivo</i>. Moreover, we found that SAMHD1 deficiency induced DNA damage and promoted the expression of DNA damage adaptor STING. STING overexpression promoted the formation of Caspase 8/RIPK3/ASC, further leading to MLKL phosphorylation, Caspase 3 cleavage, and GSDME cleavage. Up-regulation of necroptotic, apoptotic, and pyroptotic effectors indicated STING-mediated PANoptosis. Finally, we demonstrated that the STING agonist, DMXAA, enhanced the efficacy of a PD-L1 inhibitor in DLBCL. Our findings highlight the important role of STING-mediated PANoptosis in restricting DLBCL progression and provide a potential strategy for enhancing the efficacy of immune checkpoint inhibitor agents in DLBCL.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yiqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaomin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tiange</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaosheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Mengfei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhuoya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shunfeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiarui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiangxiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Biol Sci</MedlineTA><NlmUniqueID>101235568</NlmUniqueID><ISSNLinking>1449-2288</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D009713">Nucleotidyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.5.-</RegistryNumber><NameOfSubstance UI="D000076106">SAM Domain and HD Domain-Containing Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.5.-</RegistryNumber><NameOfSubstance UI="C484280">SAMHD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C532857">STING1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060890" MajorTopicYN="Y">B7-H1 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009713" MajorTopicYN="N">Nucleotidyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076106" MajorTopicYN="Y">SAM Domain and HD Domain-Containing Protein 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLBCL</Keyword><Keyword MajorTopicYN="N">DMXAA.</Keyword><Keyword MajorTopicYN="N">PANoptosis</Keyword><Keyword MajorTopicYN="N">SAMHD1</Keyword><Keyword MajorTopicYN="N">STING</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37781035</ArticleId><ArticleId IdType="pmc">PMC10535696</ArticleId><ArticleId IdType="doi">10.7150/ijbs.85236</ArticleId><ArticleId IdType="pii">ijbsv19p4627</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A. et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017;171:481&#x2013;94. e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659841</ArticleId><ArticleId IdType="pubmed">28985567</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Zhang X, Wei J, Yang C, Tong H, Mai W. et al. Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center. Exp Hematol Oncol. 2022;11:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9479281</ArticleId><ArticleId IdType="pubmed">36114573</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R. et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135:996&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099331</ArticleId><ArticleId IdType="pubmed">31977002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol. 2021;14:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180036</ArticleId><ArticleId IdType="pubmed">34090506</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Zhou X, Wang X. Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives. Cancer Res. 2022;82:2955&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437558</ArticleId><ArticleId IdType="pubmed">35771627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesin L, Ersching J, Victora GD. Germinal Center B Cell Dynamics. Immunity. 2016;45:471&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123673</ArticleId><ArticleId IdType="pubmed">27653600</ArticleId></ArticleIdList></Reference><Reference><Citation>Restelli V, Lupi M, Chila R, Vagni M, Tarantelli C, Spriano F. et al. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Mol Cancer Ther. 2019;18:1255&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">31064869</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E. et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A. 2013;110:14272&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3761606</ArticleId><ArticleId IdType="pubmed">23858451</ArticleId></ArticleIdList></Reference><Reference><Citation>Daddacha W, Koyen AE, Bastien AJ, Head PE, Dhere VR, Nabeta GN. et al. SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. Cell Rep. 2017;20:1921&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576576</ArticleId><ArticleId IdType="pubmed">28834754</ArticleId></ArticleIdList></Reference><Reference><Citation>Coquel F, Silva MJ, Techer H, Zadorozhny K, Sharma S, Nieminuszczy J. et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature. 2018;557:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">29670289</ArticleId></ArticleIdList></Reference><Reference><Citation>Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L. et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun. 2019;10:3475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6677770</ArticleId><ArticleId IdType="pubmed">31375673</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellvi M, Felip E, Ezeonwumelu IJ, Badia R, Garcia-Vidal E, Pujantell M, Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers (Basel) 2020. 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7140116</ArticleId><ArticleId IdType="pubmed">32197329</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadersten M, Lilienthal I, Tsesmetzis N, Lourda M, Bengtzen S, Bohlin A, Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. J Intern Med. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9643609</ArticleId><ArticleId IdType="pubmed">35934913</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell. 2014;54:289&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24766893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10:26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151642</ArticleId><ArticleId IdType="pubmed">31852718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T. et al. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell. 2021;39:96&#x2013;108. e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9477183</ArticleId><ArticleId IdType="pubmed">33338425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J Clin Invest. 2021. 131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843232</ArticleId><ArticleId IdType="pubmed">33290271</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: STING agonists in cancer therapy. Oncoimmunology. 2020;9:1777624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7466854</ArticleId><ArticleId IdType="pubmed">32934881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Kang R, Tang D. The STING1 network regulates autophagy and cell death. Signal Transduct Target Ther. 2021;6:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172903</ArticleId><ArticleId IdType="pubmed">34078874</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J. et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13:110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418434</ArticleId><ArticleId IdType="pubmed">32778143</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren E, Fuchs Y. Modes of Regulated Cell Death in Cancer. Cancer Discov. 2021;11:245&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">33462123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40:e106700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7917554</ArticleId><ArticleId IdType="pubmed">33439509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsch M, Gunther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31748744</ArticleId></ArticleIdList></Reference><Reference><Citation>Samir P, Malireddi RKS, Kanneganti TD. The PANoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (PANoptosis) Front Cell Infect Microbiol. 2020;10:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283380</ArticleId><ArticleId IdType="pubmed">32582562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:4641&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405902</ArticleId><ArticleId IdType="pubmed">34504660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P, Ke ZR, Chen JX, Li SJ, Ma TL, Fan XL. Advances in mechanism and regulation of PANoptosis: Prospects in disease treatment. Front Immunol. 2023;14:1120034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9948402</ArticleId><ArticleId IdType="pubmed">36845112</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Sundaram B, Sharma BR, Lee S, Malireddi RKS, Nguyen LN. et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell Rep. 2021;37:109858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853634</ArticleId><ArticleId IdType="pubmed">34686350</ArticleId></ArticleIdList></Reference><Reference><Citation>Messmer MN, Snyder AG, Oberst A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ. 2019;26:115&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294769</ArticleId><ArticleId IdType="pubmed">30341424</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Jiang S, Liang L, He H, Liu Y, Cong L. et al. Analysis of PANoptosis-Related LncRNA-miRNA-mRNA Network Reveals LncRNA SNHG7 Involved in Chemo-Resistance in Colon Adenocarcinoma. Front Oncol. 2022;12:888105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133343</ArticleId><ArticleId IdType="pubmed">35646635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi KA, Brown LE, Prakash S, Bhargava P. New developments in non-Hodgkin lymphoid malignancies. Pathology. 2021;53:349&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">33685720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X. et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298789</ArticleId><ArticleId IdType="pubmed">32546241</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Han Y, Hu S, Cai Y, Yang J, Ren S. et al. Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3eta. Front Cell Dev Biol. 2021;9:667800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111223</ArticleId><ArticleId IdType="pubmed">33987186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Bai XC, Chen ZJ. Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway. Immunity. 2020;53:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32668227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Guan W. STING Signaling Promotes Apoptosis, Necrosis, and Cell Death: An Overview and Update. Mediators Inflamm. 2018;2018:1202797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286756</ArticleId><ArticleId IdType="pubmed">30595664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265413</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li F, Zhang X, Zhang H, Zhao Q, Li M. et al. Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to prevent lymphopenia. Cell Death Differ. 2022;29:1500&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345959</ArticleId><ArticleId IdType="pubmed">35064213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y. et al. Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. Clin Cancer Res. 2018;24:6066&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30061362</ArticleId></ArticleIdList></Reference><Reference><Citation>Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Rouxel N, Briault S. et al. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS) Cell Death Dis. 2022;13:269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8953969</ArticleId><ArticleId IdType="pubmed">35338116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Pandian N, Han JH, Sundaram B, Lee S, Karki R. et al. Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method. Cell Mol Life Sci. 2022;79:531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9545391</ArticleId><ArticleId IdType="pubmed">36169732</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P. et al. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep. 2016;15:2357&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5116809</ArticleId><ArticleId IdType="pubmed">27264175</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Wang H, Ding W, Huang J, Zhou X, Wang H. et al. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci Adv. 2020;6:eabc3646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455183</ArticleId><ArticleId IdType="pubmed">32923651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7:283ra52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504692</ArticleId><ArticleId IdType="pubmed">25877890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D. et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635115</ArticleId><ArticleId IdType="pubmed">26239088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Xu Q, Huang L, Jin J, Zuo X, Zhang Q. et al. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 2021;500:163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33278498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ. et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer. 2017;36:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732416</ArticleId><ArticleId IdType="pubmed">29246182</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT. et al. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res. 2005;11:4241&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15930363</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Lv DW, Li R. Conserved Herpesvirus Protein Kinases Target SAMHD1 to Facilitate Virus Replication. Cell Rep. 2019;28:449&#x2013;59. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668718</ArticleId><ArticleId IdType="pubmed">31291580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Qiao M, Chen Y, Tang H, Zhang W, Tang D. et al. Cyclin E2-CDK2 mediates SAMHD1 phosphorylation to abrogate its restriction of HBV replication in hepatoma cells. FEBS Lett. 2018;592:1893&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">29782647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Bonifati S, Qin Z, St Gelais C, Kodigepalli KM, Barrett BS. et al. SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-kappaB and interferon pathways. Proc Natl Acad Sci U S A. 2018;115:E3798&#x2013;E807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910870</ArticleId><ArticleId IdType="pubmed">29610295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn J, Ruiz P, Barber GN. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J Immunol. 2014;193:4634&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003413</ArticleId><ArticleId IdType="pubmed">25261479</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Nowsheen S, Deng M. DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. Cancers (Basel) 2023. 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10000854</ArticleId><ArticleId IdType="pubmed">36900418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunphy G, Flannery SM, Almine JF, Connolly DJ, Paulus C, Jonsson KL. et al. Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-kappaB Signaling after Nuclear DNA Damage. Mol Cell. 2018;71:745&#x2013;60. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127031</ArticleId><ArticleId IdType="pubmed">30193098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664154</ArticleId><ArticleId IdType="pubmed">19776740</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GR, Salazar Arcila C, Hallihan LJ, Scheidl-Yee T, Jirik FR. Inducible generalized activation of hSTING-N154S expression in mice leads to lethal hypercytokinemia: a model for "cytokine storm". J Leukoc Biol. 2023;113:326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">36861228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Liu A, Xia N, Chen N, Meurens F, Zhu J. How the Innate Immune DNA Sensing cGAS-STING Pathway Is Involved in Apoptosis. Int J Mol Sci. 2023. 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9917431</ArticleId><ArticleId IdType="pubmed">36769349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning X, Wang Y, Jing M, Sha M, Lv M, Gao P. et al. Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3. Mol Cell. 2019;74:19&#x2013;31. e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30878284</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517:311&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25592536</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Hong M, Li Y, Chen D, Wu Y, Hu Y. Programmed Cell Death Tunes Tumor Immunity. Front Immunol. 2022;13:847345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005769</ArticleId><ArticleId IdType="pubmed">35432318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K. et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022;7:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882671</ArticleId><ArticleId IdType="pubmed">35221331</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia LR, Tenev T, Newman R, Haich RO, Liccardi G, John SW. et al. Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance. Nat Commun. 2021;12:3364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184782</ArticleId><ArticleId IdType="pubmed">34099649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs SB, Miao EA. Gasdermins: Effectors of Pyroptosis. Trends Cell Biol. 2017;27:673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565696</ArticleId><ArticleId IdType="pubmed">28619472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S. et al. Combination of oral STING agonist MSA-2 and anti-TGF-beta/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022;15:142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548169</ArticleId><ArticleId IdType="pubmed">36209176</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. 2021. 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256839</ArticleId><ArticleId IdType="pubmed">34215690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin M, Hu J, Yuan Z, Luo G, Yao J, Wang R. et al. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-beta signalling pathway. Cell Cycle. 2022;21:767&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8973354</ArticleId><ArticleId IdType="pubmed">35130108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Shi F, Liu Y, Zhang Y, Dong L, Li X. et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. J Hematol Oncol. 2021;14:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259370</ArticleId><ArticleId IdType="pubmed">34225766</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu M, Yang H, Kucuk C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667634</ArticleId><ArticleId IdType="pubmed">36384676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Chai F, He Y, Zhou Z, Guo S, Li P. et al. Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. Commun Biol. 2022;5:887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9427764</ArticleId><ArticleId IdType="pubmed">36042378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Gao H, Huang S, Cao T, Zhai X, Hu J. et al. Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress. Gene. 2022;851:146962.</Citation><ArticleIdList><ArticleId IdType="pubmed">36272651</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>